Amgen Inc.

Phase II trial data released on twice-yearly injection therapy

Published in Hospital and Nursing Home Week, October 28th, 2004

Amgen Inc. (Nasdaq:AMGN) announced that at all doses studied, twice yearly injections of AMG 162, the company's investigational therapy for bone loss, significantly increased bone mineral density (BMD) at the total hip compared with placebo at 12 months.

AMG 162, at all doses, also increased total hip BMD, similar to or greater than that resulting from Fosamax (alendronate; Merck) treatment in the same time frame.

The 1-year results of the ongoing multicenter, Phase II dose-ranging trial in healthy postmenopausal women with low BMD were presented at the American Society for Bone and Mineral Research 26th Annual Meeting in Seattle. The double-blind...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hospital and Nursing Home Week

Source: Hospital and Nursing Home Week (2004-10-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry